Abcam, ab224274, Anti-MBD2 antibody [EPR18361] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MBD2 antibody. Carrier free. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18361,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, IP, IHC-P, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab224274 is the carrier-free version of
ab188474
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MBD2 also known as methyl-CpG-binding domain protein 2 is a protein with a molecular mass of about 45 kDa. This protein binds to methylated DNA specifically at CpG islands and plays a role in gene silencing. MBD2 is expressed in various tissues throughout the body including the brain liver and spleen. It contains a methyl-CpG-binding domain which facilitates its interaction with methylated DNA sequences influencing the transcription of particular genes.
Biological function summary
MBD2 functions as a transcriptional repressor. It is part of the MeCP1 complex which includes proteins such as MTA2 and HDAC1. This complex remodels chromatin structure to suppress gene expression. MBD2's ability to recruit chromatin remodeling enzymes allows it to modulate access to the underlying DNA affecting the gene activity and playing a role in cellular differentiation and development.
Pathways
The role of MBD2 is particularly important in DNA methylation and chromatin modification pathways. It interacts with the DNA methylation machinery influencing epigenetic regulation. MBD2 works closely with other proteins like MeCP2 which shares similar binding properties to control gene expression through epigenetic mechanisms. These interactions highlight its role in modulating cellular function and responding to changes in the cellular environment.
Alterations in MBD2 have been linked to various cancers and neurological disorders. MBD2 deregulation affects pathways involved in tumor suppression and its overexpression has been noted in certain aggressive forms of cancer. In the context of neurological disorders MBD2 together with its related protein MeCP2 is implicated in conditions like Rett syndrome. Understanding the role of MBD2 in these diseases offers potential therapeutic avenues in targeting epigenetic modifications for treatment.